Search

Moeen Khan

Examiner (ID: 1439)

Most Active Art Unit
2436
Art Unit(s)
2436
Total Applications
231
Issued Applications
116
Pending Applications
61
Abandoned Applications
54

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 13622161 [patent_doc_number] => 20180362632 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-20 [patent_title] => ANTI-GM-CSF ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/100063 [patent_app_country] => US [patent_app_date] => 2018-08-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19894 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 100 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16100063 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/100063
Anti-GM-CSF antibodies and uses thereof Aug 8, 2018 Issued
Array ( [id] => 14102307 [patent_doc_number] => 20190092829 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-28 [patent_title] => INHIBITION OF IL-17 PRODUCTION [patent_app_type] => utility [patent_app_number] => 15/957879 [patent_app_country] => US [patent_app_date] => 2018-04-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13865 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 102 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15957879 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/957879
INHIBITION OF IL-17 PRODUCTION Apr 18, 2018 Abandoned
Array ( [id] => 13476565 [patent_doc_number] => 20180289825 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-10-11 [patent_title] => Single Chain Fc Fusion Proteins [patent_app_type] => utility [patent_app_number] => 15/949596 [patent_app_country] => US [patent_app_date] => 2018-04-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18104 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15949596 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/949596
Single chain Fc fusion proteins Apr 9, 2018 Issued
Array ( [id] => 16756619 [patent_doc_number] => 10975157 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-04-13 [patent_title] => Anti-OX40 antibodies and diagnostic uses thereof [patent_app_type] => utility [patent_app_number] => 15/921254 [patent_app_country] => US [patent_app_date] => 2018-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 14841 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 138 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15921254 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/921254
Anti-OX40 antibodies and diagnostic uses thereof Mar 13, 2018 Issued
Array ( [id] => 13386443 [patent_doc_number] => 20180244763 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-30 [patent_title] => ANTI-TGF-BETA ANTIBODIES AND THEIR USE [patent_app_type] => utility [patent_app_number] => 15/875532 [patent_app_country] => US [patent_app_date] => 2018-01-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19232 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15875532 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/875532
Anti-TGF-b antibodies and their use Jan 18, 2018 Issued
Array ( [id] => 12794947 [patent_doc_number] => 20180156818 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-07 [patent_title] => METHODS FOR TREATMENT OF CARDIOVASCULAR DISEASE [patent_app_type] => utility [patent_app_number] => 15/858661 [patent_app_country] => US [patent_app_date] => 2017-12-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27722 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15858661 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/858661
METHODS FOR TREATMENT OF CARDIOVASCULAR DISEASE Dec 28, 2017 Abandoned
Array ( [id] => 13331245 [patent_doc_number] => 20180217160 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-02 [patent_title] => IL1RL-1 as a Cardiovascular Disease Marker and Therapeutic Target [patent_app_type] => utility [patent_app_number] => 15/849135 [patent_app_country] => US [patent_app_date] => 2017-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32030 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15849135 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/849135
IL1RL-1 as a cardiovascular disease marker and therapeutic target Dec 19, 2017 Issued
Array ( [id] => 12794962 [patent_doc_number] => 20180156823 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-07 [patent_title] => METHODS OF DETERMINING RISK OF CARDIAC ARRHYTHMIA [patent_app_type] => utility [patent_app_number] => 15/830886 [patent_app_country] => US [patent_app_date] => 2017-12-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25220 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15830886 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/830886
METHODS OF DETERMINING RISK OF CARDIAC ARRHYTHMIA Dec 3, 2017 Abandoned
Array ( [id] => 12157356 [patent_doc_number] => 20180028621 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-01 [patent_title] => 'METHODS OF INDUCING INDOLAMINE 2,3 - DIOXYGENASE (IDO)' [patent_app_type] => utility [patent_app_number] => 15/785075 [patent_app_country] => US [patent_app_date] => 2017-10-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 9957 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15785075 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/785075
METHODS OF INDUCING INDOLAMINE 2,3 - DIOXYGENASE (IDO) Oct 15, 2017 Abandoned
Array ( [id] => 12178711 [patent_doc_number] => 20180037647 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-08 [patent_title] => 'Cachexia Treatment' [patent_app_type] => utility [patent_app_number] => 15/730218 [patent_app_country] => US [patent_app_date] => 2017-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 5742 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15730218 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/730218
Cachexia treatment Oct 10, 2017 Issued
Array ( [id] => 13399921 [patent_doc_number] => 20180251503 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-06 [patent_title] => MULTIMERIZATION TECHNOLOGIES [patent_app_type] => utility [patent_app_number] => 15/715499 [patent_app_country] => US [patent_app_date] => 2017-09-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20888 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15715499 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/715499
MULTIMERIZATION TECHNOLOGIES Sep 25, 2017 Abandoned
Array ( [id] => 15882871 [patent_doc_number] => 10647767 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-05-12 [patent_title] => Anti-GM-CSF antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 15/744734 [patent_app_country] => US [patent_app_date] => 2017-09-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 12 [patent_no_of_words] => 19981 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 89 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15744734 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/744734
Anti-GM-CSF antibodies and uses thereof Sep 17, 2017 Issued
Array ( [id] => 15225099 [patent_doc_number] => 10500254 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-12-10 [patent_title] => Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen [patent_app_type] => utility [patent_app_number] => 15/695587 [patent_app_country] => US [patent_app_date] => 2017-09-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 6199 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 286 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15695587 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/695587
Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen Sep 4, 2017 Issued
Array ( [id] => 16215138 [patent_doc_number] => 10730936 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-08-04 [patent_title] => Engineered anti-TGF-b antibodies and antigen-binding fragments [patent_app_type] => utility [patent_app_number] => 15/670631 [patent_app_country] => US [patent_app_date] => 2017-08-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 14224 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 102 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15670631 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/670631
Engineered anti-TGF-b antibodies and antigen-binding fragments Aug 6, 2017 Issued
Array ( [id] => 11993987 [patent_doc_number] => 20170298142 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-19 [patent_title] => 'ANTIBODIES TO TIP-1 AND GRP78' [patent_app_type] => utility [patent_app_number] => 15/628209 [patent_app_country] => US [patent_app_date] => 2017-06-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 47 [patent_figures_cnt] => 47 [patent_no_of_words] => 17533 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15628209 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/628209
Antibodies to GRP78 Jun 19, 2017 Issued
Array ( [id] => 12657013 [patent_doc_number] => 20180110837 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-04-26 [patent_title] => METHODS AND ASSAYS RELATING TO MACROPHAGE DIFFERENTIATION [patent_app_type] => utility [patent_app_number] => 15/621062 [patent_app_country] => US [patent_app_date] => 2017-06-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30643 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15621062 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/621062
METHODS AND ASSAYS RELATING TO MACROPHAGE DIFFERENTIATION Jun 12, 2017 Abandoned
Array ( [id] => 12118850 [patent_doc_number] => 20180002436 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-01-04 [patent_title] => 'TARGETED TGFß INHIBITION' [patent_app_type] => utility [patent_app_number] => 15/617876 [patent_app_country] => US [patent_app_date] => 2017-06-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 24 [patent_no_of_words] => 22905 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15617876 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/617876
TARGETED TGFß INHIBITION Jun 7, 2017 Abandoned
Array ( [id] => 11971201 [patent_doc_number] => 20170275354 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-28 [patent_title] => 'ANTIBODIES TO M-CSF' [patent_app_type] => utility [patent_app_number] => 15/614237 [patent_app_country] => US [patent_app_date] => 2017-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 24 [patent_no_of_words] => 39529 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15614237 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/614237
Antibodies to M-CSF Jun 4, 2017 Issued
Array ( [id] => 12150101 [patent_doc_number] => 20180021365 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-01-25 [patent_title] => 'ENHANCED CANCER TREATMENT AND MONITORING USING RECOMBINANT VECTORS' [patent_app_type] => utility [patent_app_number] => 15/611722 [patent_app_country] => US [patent_app_date] => 2017-06-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 37729 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15611722 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/611722
ENHANCED CANCER TREATMENT AND MONITORING USING RECOMBINANT VECTORS May 31, 2017 Abandoned
Array ( [id] => 11963633 [patent_doc_number] => 20170267784 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-21 [patent_title] => 'SINGLE DOMAIN ANTIBODIES DIRECTED AGAINST INTRACELLULAR ANTIGENS' [patent_app_type] => utility [patent_app_number] => 15/608255 [patent_app_country] => US [patent_app_date] => 2017-05-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 24 [patent_no_of_words] => 37940 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15608255 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/608255
SINGLE DOMAIN ANTIBODIES DIRECTED AGAINST INTRACELLULAR ANTIGENS May 29, 2017 Abandoned
Menu